Hukumomin Turai sun amince da rigakafin farko na yankin don kamuwa da cutar syncytial na numfashi (RSV), wanda ke haifar da dubban asibitoci da mutuwa kowace shekara.
Harbin, mai suna Arexvy, wani kamfanin sarrafa magunguna na Burtaniya GSK (GSK.L) ne ya yi kuma an yi shi ne don kare mutanen da suka kai shekaru 60 zuwa sama. RSV yawanci yana haifar da alamun sanyi-kamar bayyanar cututtuka, amma shine babban dalilin ciwon huhu a cikin jarirai da tsofaffi.
Rukunin tsarin kwayoyin cutar da kuma matsalolin tsaro tare da yunƙurin rigakafin da suka gabata sun kawo cikas ga ƙoƙarin samun nasarar samar da harbi tun lokacin da aka fara gano cutar a cikin 1956.
Amincewa da Hukumar Tarayyar Turai a ranar Laraba, wanda ya biyo bayan amincewa da kwanan nan daga Hukumar Kula da Magunguna ta Turai, ya zo ne kusan wata guda bayan da hukumar kula da lafiya ta Amurka ta ba Arexvy haske.
Samuwar maganin a Turai zai dogara ne da shawarwarin ƙasa da kuma tattaunawa game da biyan kuɗi, amma ana sa ran ƙaddamar da farko a wannan kaka kafin lokacin RSV na 2023/2024, in ji GSK a ranar Laraba. Kamfanin ba ya tsammanin za a sami gagarumin ci gaba a Turai a wannan shekara, babban jami’in kasuwanci na GSK Luke Miels ya shaida wa manema labarai
GSK, daya daga cikin manyan masu yin rigakafin rigakafi a duniya, yana dogaro da wani bangare akan Arexvy don fitar da ci gaba na dogon lokaci, tare da asarar kariya ta haƙƙin mallaka don mahimmin ƙwayar ƙwayar cuta ta HIV da koma baya a cikin fayil ɗin oncology na kasuwa.
Hukumar Kula da Abinci da Magunguna ta Amurka ta kuma amince da irin wannan harbin, Abrysvo, daga abokin hamayyar Pfizer (PFE.N) a makon jiya.
Leave a Reply